ClinicalTrials.gg
RecruitingNCT06291402Updated Jan 6, 2026

Nasal Packing Duration and Development of Pharyngitis After Septorhinoplasty Surgery

An observational study in Rhinitis, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by Al-Azhar University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
20 Years to 40 Years
Sex
All
01

Study summary

Septoplasty or septal reconstruction is a corrective surgical procedure performed to straighten the nasal septum. It may be associated with numerous complications. To minimize these complications, both nasal cavities are frequently packed with different types of nasal packing. In our study we will try to find relationship between duration of nasal packing and postrhinoplasty sore throat and pharyngitis.

Read the detailed description

Nasal packing affects swallowing by different mechanisms. It may affect swallowing as a result of nasal congestion, constant mouth breathing, throat dryness and pharyngitis.

Postoperative sore throat causes patient dissatisfaction and poor pain control. Several interventions could be performed to reduce sore throat and pharyngitis and increase patient satisfaction , which may not be convenient for all patients, such as gargling or sprays

02

Conditions studied

  • Rhinitis

Browse trials for

03

In context

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

This study's planned enrollment of 100 is below the median of 246 across 52 observational studies indexed under Rhinitis.

Browse Rhinitis studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 531 studies on the registry; 172 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

100 ASA I and II patients aged from 20 to 40 years old will undergo septorhinoplasty in Benha university hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • and II patients
  • aged from 20 to 40 years old
  • undergo septorhinoplasty

Exclusion criteria

Exclusion Criteria:

  • Bleeding disorders
  • Uncontrolled hypertension
  • Cardiovascular diseases
  • Uncontrolled diabetes mellitus
  • Collagen disorders
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Sore throat

    The incidence of Sore throat will be graded as 0 = Nil, 1 = Mild, 2 = Moderate and 3 = Severe as possible.

    Time frame: 48 hours postoperatively

Secondary outcomes

  1. Dysphagia

    The incidence of Dysphagia will be recorded

    Time frame: 48 hours postoperatively

  2. Throat irritation

    The incidence of throat irritation will be recorded

    Time frame: 48 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data will be shared upon reasonable request from the principle investigator

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 13 observational studies under Rhinitis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2024
First posted
Mar 4, 2024
StartActual
Mar 10, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06291402
Collaborators
Benha University
Responsible party
Neveen Abd El Maksoad Kohaf (Lecturer of Clinical Pharmacy, Al-Azhar University) — Principal investigator
First posted
Mar 4, 2024
Start date
Mar 10, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Jan 6, 2026

Study contacts

Neveen Kohaf, Ph.D
Contact
nevenabdo@azhar.edu.eg
+201060383012
Neveen Kohaf
Contact
nevenabdo@azhar.edu.eg
+201060383012
Neveen Kohaf, ph.d
principal investigator · Al-Azhar University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion